Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...

Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...

Hims & Hers Health (NYSE: HIMS) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed ...

Hims & Hers Health Inc. is expanding beyond its successful foray into providing copycat weight-loss drugs with the ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...

Hims is a US-based telehealth company offering online prescription medication, over-the-counter drugs, and personal care ...

Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.

BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last three months.